维莫德吉治疗3例Basocellular皮肤癌患者的作用机制综述

Cancer Therapy & Oncology International Journal Pub Date : 2020-08-07 DOI:10.19080/CTOIJ.2020.16.555945

A. Hunis

{"title":"维莫德吉治疗3例Basocellular皮肤癌患者的作用机制综述","authors":"A. Hunis","doi":"10.19080/CTOIJ.2020.16.555945","DOIUrl":null,"url":null,"abstract":"Vismodegib (Erivedge®) is a hedgehog pathway inhibitor and is approved to treat locally advanced or metastatic basal cell carcinoma (BCC) not suitable for surgery or radiation therapy. Our main objectives were to study the intimate mechanism of action of this novel drug and to present three cases of our casuistry, the clinically evaluated objective response rate (ORR), as a contribution to the literature.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"867 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Basocellular Skin Cancer about Three Patients Treated with Vismodegib Review of your Action Mechanism\",\"authors\":\"A. Hunis\",\"doi\":\"10.19080/CTOIJ.2020.16.555945\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Vismodegib (Erivedge®) is a hedgehog pathway inhibitor and is approved to treat locally advanced or metastatic basal cell carcinoma (BCC) not suitable for surgery or radiation therapy. Our main objectives were to study the intimate mechanism of action of this novel drug and to present three cases of our casuistry, the clinically evaluated objective response rate (ORR), as a contribution to the literature.\",\"PeriodicalId\":9575,\"journal\":{\"name\":\"Cancer Therapy & Oncology International Journal\",\"volume\":\"867 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Therapy & Oncology International Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.19080/CTOIJ.2020.16.555945\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Therapy & Oncology International Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/CTOIJ.2020.16.555945","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Vismodegib (Erivedge®)是一种刺猬通路抑制剂，被批准用于治疗局部晚期或转移性基底细胞癌(BCC)，不适合手术或放射治疗。我们的主要目的是研究这种新药的内在作用机制，并提出我们的三个病例，临床评估的客观反应率(ORR)，作为对文献的贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Basocellular Skin Cancer about Three Patients Treated with Vismodegib Review of your Action Mechanism

Vismodegib (Erivedge®) is a hedgehog pathway inhibitor and is approved to treat locally advanced or metastatic basal cell carcinoma (BCC) not suitable for surgery or radiation therapy. Our main objectives were to study the intimate mechanism of action of this novel drug and to present three cases of our casuistry, the clinically evaluated objective response rate (ORR), as a contribution to the literature.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Therapy & Oncology International Journal

自引率

0.00%

发文量